Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

732
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
732
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

692
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
692
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

270
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
270
Prosopagnosia01:24

Prosopagnosia

288
Prosopagnosia, also known as face blindness, is the inability to recognize faces. In severe cases, individuals with prosopagnosia may not recognize close family members, including parents and spouses, by their faces. For instance, someone with prosopagnosia might walk past their child in a crowd, only realizing their mistake upon noticing their child's distinctive backpack or favorite jacket. Prosopagnosia specifically impairs facial recognition, while the recognition of other objects or...
288
Visual Agnosia01:12

Visual Agnosia

340
Visual agnosia is a condition characterized by the inability to recognize visually presented objects despite having normal vision. For instance, a person with visual agnosia can describe the shape and color of an object but cannot identify or name it. This impairment does not affect their visual field, acuity, color vision, brightness discrimination, language, or memory. An example of this condition in a social setting is someone at a dinner party asking for "that silver thing with a round...
340
Higher Mental Functions of the Brain: Language01:10

Higher Mental Functions of the Brain: Language

1.0K
Language is a system of communication that allows the expression of thoughts, ideas, and feelings. The brain processes language in both hemispheres.
Language formation and comprehension take place in the dominant hemisphere. The dominant hemisphere is responsible for understanding the meaning of spoken, written, or sign language, as well as the ability to communicate. For most people, the left hemisphere is the dominant one. The right hemisphere, then, gives tone and emotional context to the...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants.

medRxiv : the preprint server for health sciences·2026
Same author

Beyond language: A structured profile of number processing impairment in logopenic primary progressive aphasia.

Journal of Alzheimer's disease : JAD·2026
Same author

Impairment of written word production in logopenic primary progressive aphasia: dissociating phonological and orthographic contributions.

Frontiers in human neuroscience·2026
Same author

Cognitive characterization of the behavioral variant of frontotemporal dementia using the Neuronorma battery.

Journal of Alzheimer's disease : JAD·2026
Same author

Toward a Diagnostic Template for Acquired Apraxia of Speech: Insights From an Academy of Neurologic Communication Disorders Review.

American journal of speech-language pathology·2026
Same author

Diagnostic accuracy of the Multicultural Cognitive Examination (MCE) for detection of MCI and dementia in a diverse international cohort.

The Clinical neuropsychologist·2026

Related Experiment Video

Updated: Sep 21, 2025

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
13:12

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping

Published on: August 12, 2019

45.8K

Advances in Primary Progressive Aphasia.

Jordi A Matias-Guiu1, Robert Laforce2, Monica Lavoie2

  • 1Department of Neurology, Hospital Clínico San Carlos, Health Research Institute "San Carlos" (IdISCC), Universidad Complutense de Madrid, 28040 Madrid, Spain.

Brain Sciences
|May 28, 2022
PubMed
Summary

Primary progressive aphasia (PPA) is a neurodegenerative disease impacting language skills over time. Research focuses on understanding its progressive nature and language deficits.

More Related Videos

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia
10:15

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia

Published on: July 2, 2013

18.0K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.6K

Related Experiment Videos

Last Updated: Sep 21, 2025

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
13:12

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping

Published on: August 12, 2019

45.8K
Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia
10:15

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia

Published on: July 2, 2013

18.0K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.6K

Area of Science:

  • Neurology
  • Linguistics

Background:

  • Primary progressive aphasia (PPA) is a rare neurodegenerative condition.
  • It is defined by gradual deterioration of language abilities.

Discussion:

  • PPA presents a unique challenge in differentiating from other dementias.
  • Understanding the specific language impairments is crucial for diagnosis.

Key Insights:

  • The core feature of PPA is progressive language decline.
  • Early and accurate diagnosis impacts patient management.

Outlook:

  • Further research is needed to explore PPA subtypes.
  • Developing targeted therapies for PPA is a priority.